Welcome to the website for the THRIVE clinical research study.

The THRIVE study is a clinical research study of an investigational oral drug for the treatment of moderate to severe alopecia areata.

This clinical research study is now enrolling adults between the ages of 18 to 65 who have been diagnosed with alopecia areata and have a current episode of hair loss for at least 6 months and not exceeding 10 years. Note that you can be diagnosed with alopecia areata more than 10 years ago to qualify.

To learn about participating or to see if there is a clinical research study location near you, scroll down or click on the page links.

To see if you may be able to participate, please complete our pre-qualifying questionnaire.

Has a medical professional told you that you have alopecia areata?
(“Alopecia areata” includes alopecia areata, alopecia totalis, and alopecia universalis.
“Alopecia areata” DOES NOT include alopecia androgenic, alopecia diffuse, or alopecia frontal – if you have alopecia androgenic, diffuse, or frontal, you should answer “no” to this question.)
How did you hear about this clinical research study?
Please enter your home or work zip code. This zip code will be used to locate a clinical study center near you. Please provide the zip code that would be most convenient to you.
Enter 5-digit zip code
Are you currently between the ages of 18 to 65?
Have you been experiencing hair loss due to alopecia areata for at least the last 6 months but not exceeding 10 years? Note that you can be diagnosed with alopecia areata more than 10 years ago to qualify.

By clicking you authorize us to proceed with the pre-screening process and to begin recording your answers. By clicking you also consent to the terms of the Privacy Policy. Your name and contact information will not be associated with your answers unless you provide this information after you complete the pre-qualifying questionnaire.

Why is this Clinical Research Study Important?

Alopecia areata is a condition that causes hair loss on the scalp and/or body, with patchy hair loss affecting the scalp being the most common type. This often occurs in cycles of unpredictable hair loss and spontaneous regrowth. Nearly 2% of the general population will be affected by alopecia areata at some point in their lifetimes. In some cases, alopecia areata can be associated with high rates of depression and anxiety. The investigational oral drug is intended to treat the underlying autoimmune process that results in hair loss from alopecia areata. There is currently no approved medication that treats the cause of hair loss from alopecia areata.

Before new medications can be approved for public use, they must be tested in clinical research studies like this one. The THRIVE clinical study will look at the safety and effectiveness of the investigational oral drug on hair loss associated with alopecia areata.

Click here to learn more about this study.
Participating Cities
Please check back regularly to see if a site is added in your area.

  • Alabama
    •  Birmingham
  • Arizona
    •  Scottsdale
  • California
    •  Bakersfield
    •  Canoga Park
    •  Encinitas
    •  Northridge
    •  Oakland
    •  Palm Springs
  • Colorado
    •  Centennial
    •  Denver
  • Florida
    •  Boca Raton
    •  Hollywood
  • Georgia
    •  Newnan
  • Illinois
    •  Chicago
  • Indiana
    •  Plainfield
  • Kentucky
    •  Louisville
  • Michigan
    •  Clarkston
  • Minnesota
    •  Minneapolis
    •  New Brighton
  • Nebraska
    •  Omaha
  • North Carolina
    •  Charlotte
    •  Raleigh
  • Ohio
    •  Columbus
  • Oregon
    •  Portland
  • Pennsylvania
    •  Plymouth Meeting
  • Rhode Island
    •  Providence
  • Texas
    •  Dallas
    •  Pflugerville
  • Utah
    •  Springville

What is Clinical Research?

Although there are many definitions, a clinical research study is generally considered to be health-related clinical research in people with a specific condition using a pre-defined written protocol.

Click here to learn more about clinical research.